Related Experiment Video
Updated: Feb 18, 2026

Author Spotlight: Developing Acetyl-Click Assay for HAT1 Inhibitor Screening
Published on: January 26, 2024
Histone acetyltransferase HAT1 drives malignant progression in lower-grade glioma: reshaping the immune
Zhi Sha1, Zongye Zhang1, Han Liu2
1Zhengzhou University People's Hospital, Henan Provincial People's Hospital, China.
Background:
HAT1's role in lower-grade glioma (LGG) malignancy and mechanisms is unclear.
Methods:
Multi-omics analysis (TCGA/CGGA transcriptomics, single-cell/spatial transcriptomics, IHC/RT-qPCR) of 906 LGG patients assessed HAT1 expression, prognosis, pathways, immune infiltration, and cellular localization. Molecular docking screened HAT1-targeting drugs.
Results:
HAT1 was significantly upregulated in LGG vs. normal brain, correlating with IDH-wildtype status, recurrence, and worse overall survival (independent risk factor). It specifically enriched malignant cell regions. HAT1 overexpression activated cell cycle, adherens junctions, and RIG-I-like signaling. It promoted immune cell infiltration and checkpoint expression. Top FDA-approved compounds with strong binding affinity were identified.
Conclusions:
HAT1 drives LGG malignancy by remodeling the immune microenvironment and activating key oncogenic pathways. Its spatial enrichment in malignant niches and druggability provide a novel basis for targeted-immunotherapy combinations.
Related Concept Videos
Tumor Progression
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
lncRNA - Long Non-coding RNAs
mTOR Signaling and Cancer Progression
The mTOR pathway or the...
Abnormal Proliferation

